ArticleThe Pan African medical journal2026
[Descriptive analytical study of patient survival with vertebral metastases in a rheumatological setting in Togo].
Article in The Pan African medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastases, especially bone metastases, are common during the progression of certain cancers and most often threaten the patient's life or sometimes their functional prognosis (spinal cord compression). The objective of this study is to evaluate the survival of patients with vertebral metastases in Togo. We conducted a retrospective, cross-sectional, descriptive, and analytical study over 5 years, from 2016 to 2020, in the Rheumatology Departments of Kara University Hospital, Sylvanus Olympio, and Bè Hospital in Togo, including all patients diagnosed with bone and/or visceral metastases from a primary tumor. The Tokuhashi score was used. Multivariate regression analysis was performed to identify associated factors. We collected data on 82 patients, predominantly male (53 men, 64.63%), with a mean age of 65 years for the men. Prostate cancer was found in 46 patients (56.09%), followed by breast cancer in 12 patients (14.63%). Factors statistically associated with poor prognosis were the presence of a radiographic lytic image (ORa: 3.87; 95% CI: 1.66 - 4.85) and a mixed image (ORa: 2.58; 95% CI: 1.38 - 4.74) with p<0.004 and p<0.001, respectively. In our study, 63.3% of patients with a poor prognosis survived less than 6 months (ORa: 4.99; 95% CI: 7.26 - 40.0) with p = 0.001. A multivariate analysis between the most frequent tumors and survival according to the Tokuhashi score found that prostate cancer (n = 46) was associated with a median actual survival of 17.9 months (OR: 0.23; 95% CI: 0.11-0.48), versus a Tokuhashi score predicted survival of 9.87 months. Breast cancer (n = 12) showed an actual survival of 9.87 months (OR: 0.48; 95% CI: 0.21-1.14) with a predicted survival of 8.92 months. Bone metastases are associated with significant morbidity and patient survival. The presence of a lytic radiographic image and a mixed image are statistically significant factors of poor prognosis. Prostate cancer and breast cancer are the most frequent cancers and are statistically associated with patient survival according to the Tokuhashi score, with an actual survival of 17.9 months against a Tokuhashi score-predicted survival of 9.87 months, and breast cancer with an actual survival of 9.87 months against a predicted survival of 8.82.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.